FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

 

For period ending 22 February 2019

 

GlaxoSmithKline plc

(Name of registrant)

 

 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

 

 

 

Form 20-F x     Form 40-F

 

--

 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

 

 

 

Yes      No x

 

 

Issued: 22 February 2019, London UK - LSE Announcement

 

GSK response to SFO Statement

 

 

In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.

 

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

 

 

GSK enquiries:
UK Media enquiries:	Simon Steel	+44 (0) 20 8047 5502	(London)
	Tim Foley	+44 (0) 20 8047 5502	(London)
Analyst/Investor enquiries:	Sarah Elton-Farr	+44 (0) 208 047 5194	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)

 

Cautionary statements regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GlaxoSmithKline plc
	(Registrant)
Date: February 22, 2019
	By: VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GlaxoSmithKline plc